171 related articles for article (PubMed ID: 24977378)
1. Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs.
Xu W; Wang Q; Yu F; Lu L; Jiang S
J Acquir Immune Defic Syndr; 2014 Sep; 67(1):1-6. PubMed ID: 24977378
[TBL] [Abstract][Full Text] [Related]
2. Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains.
Yu F; Li W; Wang L; Dai Y; Lu X; Wang Q; Xie L; Jiang S
Molecules; 2018 Jul; 23(7):. PubMed ID: 30004408
[TBL] [Abstract][Full Text] [Related]
3. New antiretroviral drugs.
Gulick RM
Clin Microbiol Infect; 2003 Mar; 9(3):186-93. PubMed ID: 12667250
[TBL] [Abstract][Full Text] [Related]
4. The development of anti-HIV-1 drugs.
Lu XF; Chen ZW
Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
[TBL] [Abstract][Full Text] [Related]
5. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
Joly V; Descamps D; Yeni P
AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
7. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.
Vermeire K; Princen K; Hatse S; De Clercq E; Dey K; Bell TW; Schols D
AIDS; 2004 Nov; 18(16):2115-25. PubMed ID: 15577644
[TBL] [Abstract][Full Text] [Related]
8. Newer antiretroviral agents and how to use them.
Kim HH; Daar ES
Curr HIV/AIDS Rep; 2009 May; 6(2):55-62. PubMed ID: 19358775
[TBL] [Abstract][Full Text] [Related]
9. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients.
Birk M; Sönnerborg A
AIDS; 1998 Dec; 12(18):2369-75. PubMed ID: 9875574
[TBL] [Abstract][Full Text] [Related]
10. New drugs for old.
Winston A; Stebbing J
J HIV Ther; 2005 Mar; 10(1):11-6. PubMed ID: 15951729
[TBL] [Abstract][Full Text] [Related]
11. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
[TBL] [Abstract][Full Text] [Related]
12. [Advances in novel anti-HIV-1 drugs and drug candidates: 2005-2008].
Zheng PR; Xue H; Xiao ZY; Liu G
Yao Xue Xue Bao; 2010 Feb; 45(2):154-64. PubMed ID: 21351426
[TBL] [Abstract][Full Text] [Related]
13. Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.
Essey RJ; McDougall BR; Robinson WE
Antiviral Res; 2001 Sep; 51(3):189-202. PubMed ID: 11448730
[TBL] [Abstract][Full Text] [Related]
14. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
[TBL] [Abstract][Full Text] [Related]
15. The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.
Xu W; Zhao J; Sun J; Yin Q; Wang Y; Jiao Y; Liu J; Jiang S; Shao Y; Wang X; Ma L
Antimicrob Agents Chemother; 2015 Aug; 59(8):4882-8. PubMed ID: 26055365
[TBL] [Abstract][Full Text] [Related]
16. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
17. Delavirdine: a review of its use in HIV infection.
Scott LJ; Perry CM
Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
[TBL] [Abstract][Full Text] [Related]
18. APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro.
Pereira CF; Paridaen JT; van de Bovenkamp M; Middel J; Verhoef J; Nottet HS
J Antimicrob Chemother; 2003 May; 51(5):1181-9. PubMed ID: 12668583
[TBL] [Abstract][Full Text] [Related]
19. New antiretroviral drugs.
Hanson K; Hicks C
Curr HIV/AIDS Rep; 2006 Jul; 3(2):93-101. PubMed ID: 16608666
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 antiretroviral drug therapy.
Arts EJ; Hazuda DJ
Cold Spring Harb Perspect Med; 2012 Apr; 2(4):a007161. PubMed ID: 22474613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
